0
Skip to Content
Lennham Pharmaceuticals
About
Science
Pipeline
Overview
d-Caffeine
d-Psilocybin
d-Testosterone
News
Contact
Lennham Pharmaceuticals
About
Science
Pipeline
Overview
d-Caffeine
d-Psilocybin
d-Testosterone
News
Contact
About
Science
Folder: Pipeline
Back
Overview
d-Caffeine
d-Psilocybin
d-Testosterone
News
Contact
Corey MacGregor 5/31/22 Corey MacGregor 5/31/22

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin

Read More
Corey MacGregor 1/28/22 Corey MacGregor 1/28/22

Lennham publishes manuscript detailing the nonclinical PK and safety evaluation of d9-caffeine in Food and Chemical Toxicology

Read More
Corey MacGregor 12/1/21 Corey MacGregor 12/1/21

Lennham Pharmaceuticals Announces Discovery of Next Generation Testosterone Candidate

Read More
Corey MacGregor 9/10/21 Corey MacGregor 9/10/21

Lennham Pharmaceuticals Expands Leading Psilocybin Patent Portfolio with Addition of New Patent Family

Read More
Corey MacGregor 6/18/21 Corey MacGregor 6/18/21

Lennham Presents Topline Data From Human PK Study of D9-Caffeine vs Caffeine at ISSN 2021

Read More
Corey MacGregor 6/18/21 Corey MacGregor 6/18/21

Lennham Pharmaceuticals Announces Topline Results from Pharmacokinetic Study of D9-Caffeine Versus Caffeine

Read More
Corey MacGregor 5/17/21 Corey MacGregor 5/17/21

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Deuterated Psilocybin Products

Read More

53 Main Street, Suite 206, Concord, MA | info@lennham.com